Physician profile
Nancy M Baker
NPI 1972661577
$584.20
in general payments reported to CMS, 2019-2025
12 companies · $18.42 in 2025
The $18.42 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $58.62 · 2021: $77.04 · 2022: $87.53 · 2023: $34.87 · 2024: $94.99 · 2025: $18.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $94.99 · Food and Beverage: $53.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $94.99 |
| Food and Beverage | $53.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $157.98 | 2019-2023 | |
| Astellas Pharma US INC | $112.51 | 2019-2024 | |
| Lilly USA, LLC | $75.26 | 2021-2025 | Mounjaro |
| Insmed, INC. | $66.61 | 2019 | |
| Tosoh Bioscience, INC. | $50.00 | 2019 | |
| Allergan, INC. | $27.35 | 2020 | |
| Merck Sharp & Dohme LLC | $23.49 | 2019-2020 | |
| Shire North American Group INC | $19.42 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.38 | 2021 | |
| Abbott Laboratories | $19.25 | 2020 | |
| Amgen INC. | $12.95 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$0.05 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.